IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RAVAGGI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.059
EU - Europa 2.961
AS - Asia 2.909
SA - Sud America 440
AF - Africa 67
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 13.456
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.874
CN - Cina 985
SG - Singapore 948
PL - Polonia 595
DE - Germania 519
UA - Ucraina 430
IT - Italia 406
BR - Brasile 372
HK - Hong Kong 315
GB - Regno Unito 236
FI - Finlandia 224
VN - Vietnam 205
FR - Francia 133
CA - Canada 127
TR - Turchia 95
RU - Federazione Russa 93
IE - Irlanda 87
IN - India 86
BD - Bangladesh 85
EE - Estonia 46
SE - Svezia 41
ID - Indonesia 33
MX - Messico 33
AR - Argentina 30
NL - Olanda 30
IQ - Iraq 28
ZA - Sudafrica 27
ES - Italia 23
AT - Austria 17
BE - Belgio 17
JP - Giappone 16
LT - Lituania 16
CZ - Repubblica Ceca 14
KG - Kirghizistan 11
MA - Marocco 11
AE - Emirati Arabi Uniti 10
PK - Pakistan 10
EC - Ecuador 9
EU - Europa 9
SA - Arabia Saudita 9
AU - Australia 8
KR - Corea 8
VE - Venezuela 8
BG - Bulgaria 7
UZ - Uzbekistan 7
CR - Costa Rica 6
JO - Giordania 6
NG - Nigeria 6
NP - Nepal 6
TW - Taiwan 6
CL - Cile 5
TN - Tunisia 5
CO - Colombia 4
EG - Egitto 4
IL - Israele 4
IR - Iran 4
KE - Kenya 4
KZ - Kazakistan 4
LK - Sri Lanka 4
LV - Lettonia 4
MU - Mauritius 4
MY - Malesia 4
NI - Nicaragua 4
PT - Portogallo 4
PY - Paraguay 4
AL - Albania 3
AZ - Azerbaigian 3
BB - Barbados 3
BY - Bielorussia 3
HN - Honduras 3
JM - Giamaica 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
TH - Thailandia 3
UY - Uruguay 3
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CH - Svizzera 2
ET - Etiopia 2
LU - Lussemburgo 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AQ - Antartide 1
BW - Botswana 1
DZ - Algeria 1
GD - Grenada 1
GT - Guatemala 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MT - Malta 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SN - Senegal 1
Totale 13.452
Salva come PNG Salva come JPEG
Città #
Fairfield 744
Ashburn 658
Warsaw 591
Woodbridge 563
Singapore 553
Houston 397
San Jose 335
Seattle 333
Jacksonville 308
Hong Kong 294
Chandler 292
Wilmington 263
Ann Arbor 256
Cambridge 250
New York 221
Beijing 203
The Dalles 173
Dearborn 161
Munich 158
Helsinki 150
Los Angeles 149
Princeton 149
Nanjing 102
Dublin 87
Mcallen 83
Brescia 79
Istanbul 74
Lauterbourg 73
Des Moines 59
Ho Chi Minh City 57
Shanghai 57
Dallas 49
Buffalo 48
Council Bluffs 47
Tallinn 46
Milan 45
San Francisco 44
São Paulo 43
Nanchang 42
Montréal 39
Toronto 39
Shenyang 37
Dong Ket 36
Moscow 36
Hanoi 35
London 35
Chicago 34
Jinan 33
San Diego 32
Orem 28
Santa Clara 28
Redondo Beach 27
Hebei 26
Changsha 25
Jiaxing 24
Kunming 24
Montreal 24
Tianjin 24
Denver 22
Chennai 21
Rome 21
Jakarta 19
Turku 18
Guangzhou 17
Hangzhou 17
Johannesburg 16
Phoenix 16
Brussels 14
Mexico City 14
Nuremberg 14
Tokyo 14
Zhengzhou 14
Belo Horizonte 13
Central 13
Monmouth Junction 13
Paris 13
Poplar 13
Stockholm 13
Manchester 12
Amsterdam 11
Charlotte 11
Hefei 11
Mumbai 11
Rio de Janeiro 11
Vienna 11
Bishkek 10
Boston 10
Brooklyn 9
Ningbo 9
Ankara 8
Atlanta 8
Da Nang 8
Lancaster 8
Lanzhou 8
Leawood 8
Norwalk 8
Taiyuan 8
Taizhou 8
Verona 8
Baghdad 7
Totale 9.340
Salva come PNG Salva come JPEG
Nome #
Influence of maternal CD4+ levels on the predictive value of virus load mother-to-child transmission of HIV type 1 (HIV-1) 417
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 361
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 356
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 331
Claudin3 is localized outside the tight junctions in human carcinomas 293
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 286
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 233
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 224
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 213
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 211
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 210
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 204
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 203
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 202
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 201
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 196
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 193
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 188
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 186
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 183
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 181
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 180
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 178
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 176
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 176
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 175
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 174
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 173
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 172
Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma 169
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Mammaglobin B expression in human endometrial cancer 167
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 166
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 161
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 158
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 156
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 153
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 150
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 148
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 147
Claudin-7 expression in human epithelial ovarian cancer 147
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 146
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 144
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 143
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 142
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 141
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 140
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 137
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 135
EXPRESSION PATTERN AND MOLECULAR FUNCTION OF TRASCRIPTION FACTOR FOXM1 (FORKHEAD BOX PROTEIN M1) IN EPITHELIAL OVARIAN CANCER CLINICAL SPECIMENS AND CELL LINES 133
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 133
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 130
Functional profiles of curatively treated adenoid cystic carcinoma unveil prognostic features and potentially targetable pathways 129
Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates 129
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 129
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 128
Radiation-Enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma 123
Genetic evolution of the hypervariable region 1 in hetpatitis C virus carriers with normal aminotransferase activities 123
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 120
DEVELOPMENT, CHARACTERIZATION AND DISTRIBUTION OF ADOPTIVELY TRANSFERRED PERIPHERAL BLOOD LYMPHOCYTES PRIMED BY HUMAN PAPILLOMAVIRUS 18 E7--PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ADENOCARCINOMA OF THE UTERINE CERVIX. 118
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 118
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. 117
Integrated mutational landscape analysis of uterine leiomyosarcomas 115
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 114
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 113
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 112
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 109
HE4 and epithelial ovarian cancer : Comparison and clinical evaluation of two immunoassays and a combination algorithm 106
EXPRESSION OF CD56 BY HUMAN PAPILLOMAVIRUS E7-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES CORRELATES WITH INCREASED INTRACELLULAR PERFORIN EXPRESSION AND ENHANCED CYTOTOXICITY AGAINST HLA-A2-MATCHED CERVICAL TUMOR CELLS. 102
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 97
Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody 97
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 95
Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer 91
The Oxford Classic can identify HGSOC patients who may benefit from EMT-targeting therapies 88
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 87
Serum S100A6 concentration predicts peritoneal tumor burden inmice with epithelial ovarian cancer and is associated with advanced stage in patients. 86
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 85
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study 84
Finding the junction between claudins and endometrial carcinoma 81
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study 74
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis 72
HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study 65
Oxford Classic-Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions 57
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine 56
VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients 51
Development of a diagnostic model based on serum microRNAs for the diagnosis of endometriosis 50
Mammaglobin B (SCGB2A1) is a novel tumor antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy 43
Serum miRNA-based diagnostic models for endometriosis: from discovery to validation 13
Totale 13.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202178 0 0 0 0 0 0 0 0 0 0 0 78
2021/2022772 93 121 10 15 5 48 49 39 32 132 64 164
2022/2023791 130 40 37 51 64 173 10 89 113 9 41 34
2023/2024956 49 32 93 86 47 221 53 49 163 51 15 97
2024/20251.692 18 46 21 281 147 171 104 62 165 103 356 218
2025/20263.714 374 346 255 529 439 290 579 129 235 336 137 65
Totale 13.663